MarketCap
Facebook
X
Telegram
Travere Therapeutics Financial Ratios 2025-2011 | TVTX
Brief overview of Travere Therapeutics's valuation and returns
The review covers five available annual periods spanning 2021 to 2025.
Key multiples at the end of the period are P/S 5.26x (median 9.8x), P/B 22.5x (median 22.5x). The combined multiple level is about 23.1% below the company's historical norm, suggesting more cautious expectations.
Returns on assets and capital are represented by ROE -22.2%, ROA -4.2%, ROCE -54.7%. Losses and negative capital returns make ordinary P/E-like references unstable or inapplicable.
Current PEG is 0.49x; the market pays comparatively little per unit of expected growth.
The cash cycle lengthened by 1,110.3 days to 563.7 days. Operations require more funding.
Valuation takeaway
Travere Therapeutics's restrained price comes with modest current quality. Better efficiency is needed for revaluation.
Annual Financial Ratios Travere Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-101.1 | -7.1 | -5.5 | -21.0 | -9.1 | -7.1 | - | - | - | - | - | - | - | - | - |
P/S |
5.3 | 9.8 | 4.2 | 47.2 | 12.5 | 6.1 | - | - | - | - | - | - | - | - | - |
EPS |
-0.3 | -4.1 | -1.5 | -1.0 | -3.0 | -3.6 | -3.5 | -2.5 | -1.5 | -1.3 | 3.5 | -4.4 | -2.4 | -8.3 | - |
EV (Enterprise Value) |
2.98 B | 2.76 B | 1.14 B | 1.95 B | 1.95 B | 1.51 B | 321 M | 288 M | 128 M | 177 M | 175 M | 155 M | 32.8 M | 55.6 K | 54.2 K |
EBITDA per Share |
-0.02 | -3.55 | -4.71 | -1.03 | -3.12 | -3.19 | - | - | - | - | - | - | - | - | - |
EV/EBITDA |
-14.2 | -35.2 | - | - | - | - | - | - | - | - | - | ||||
PEG |
- | 0.49 | - | - | - | - | - | - | - | - | - | ||||
P/B |
22.5 | 38.7 | 3.1 | 32.3 | 5.4 | 5.7 | - | - | - | - | - | - | - | - | - |
P/CF |
68.4 | -9.6 | -2.2 | -7.4 | -111.2 | -28.1 | - | - | - | - | - | - | - | - | - |
ROE % |
-22.25 | -544.28 | -55.47 | -153.61 | -59.61 | -80.22 | - | - | - | - | - | - | - | - | - |
ROA % |
-4.22 | -54.12 | -14.12 | -9.79 | -23.19 | -27.89 | - | - | - | - | - | - | - | - | - |
ROCE % |
-54.71 | -548.14 | -193.29 | -202.33 | -66.01 | -83.41 | - | - | - | - | - | - | - | - | - |
Current Ratio |
1.2 | 1.1 | 1.3 | 1.1 | 1.6 | 1.5 | - | - | - | - | - | - | - | - | - |
DSO |
39.9 | 37.8 | 47.5 | 202.5 | 44.1 | 31.3 | - | - | - | - | - | - | - | - | - |
DIO |
1377.0 | 1208.2 | 222.1 | 488.7 | 713.2 | 407.8 | - | - | - | - | - | - | - | - | - |
DPO |
853.2 | 1536.8 | 939.8 | 1339.2 | 1303.8 | 1154.3 | - | - | - | - | - | - | - | - | - |
Operating Cycle |
1416.9 | 1246.0 | 269.6 | 691.2 | 757.3 | 439.1 | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
563.7 | -290.8 | -670.2 | -648.0 | -546.5 | -715.2 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Travere Therapeutics
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.14 | -0.47 | - | -0.7 | -0.91 | -1.76 | - | 1.97 | -1.13 | -1.27 | - | -1.09 | -1.05 | -1.2 | - | -0.59 | -0.64 | -0.96 | -2.37 | -0.44 | -0.58 | 0.02 | -0.7 | -0.85 | -0.92 | -0.99 | -0.18 | -1.34 | -0.56 | -0.46 | -0.45 | -0.46 | -0.34 | -0.29 | -0.23 | -1 | -0.37 | 0.31 | -0.07 | 2.95 | -0.73 | 1.46 | -1.1 | -0.67 | 0.46 | -3.25 | -0.7 | -0.71 | -0.41 | -0.46 | -0.03 | -2.42 | -1.55 | -1.43 | -0.03 | -0.1 | - | - |
EBITDA per Share |
0.01 | -0.34 | - | -0.58 | -0.75 | -1.68 | - | -1.07 | -1.23 | -1.33 | - | -1.21 | -0.91 | -0.94 | - | -0.18 | -0.48 | -0.74 | -2.27 | -0.03 | -0.26 | -0.22 | -0.65 | -0.45 | -0.64 | -0.8 | -0.12 | -0.54 | -0.31 | -0.34 | -0.39 | 0.07 | -0.12 | -0.27 | -0.48 | -0.23 | -0.1 | -0.12 | -0.42 | -0.31 | -0.04 | -0.23 | -0.72 | -0.69 | -0.6 | -0.94 | -0.64 | -0.38 | -0.4 | -0.17 | - | -2.39 | -1.53 | -1.42 | - | - | - | - |
ROE % |
195.41 | -230.48 | -468.55 | -414.67 | -540.77 | -149.44 | -65.28 | -134.46 | -257.53 | -226.79 | -148.46 | -160.06 | -102.46 | -71.43 | -38.19 | -95.77 | -94.85 | -95.45 | -80.22 | -36.32 | -42.14 | -47.29 | -66.20 | -54.86 | -55.49 | -45.01 | -32.26 | -35.93 | -24.87 | -22.37 | -20.38 | -17.16 | -23.15 | -22.99 | -15.56 | -13.59 | 33.66 | 29.51 | 39.08 | 117.83 | 130.90 | 107.72 | 297.81 | 285.09 | 302.41 | 360.99 | 184.26 | 119.17 | 944.00 | 1807.53 | 2671.37 | 2671.92 | 1781.50 | 891.08 | 0.66 | - | - | - |
ROA % |
-31.54 | -42.02 | -44.15 | -26.05 | 2.92 | 4.06 | -4.21 | -13.80 | -41.49 | -39.04 | -27.93 | -32.53 | -18.37 | -23.59 | -16.87 | -36.89 | -36.01 | -35.08 | -27.89 | -12.87 | -15.19 | -17.30 | -24.21 | -20.26 | -21.91 | -18.66 | -14.48 | -16.81 | -12.55 | -11.94 | -11.48 | -9.73 | -13.38 | -13.39 | -9.12 | -7.96 | 19.71 | 17.28 | 22.89 | 1.94 | -31.94 | -18.24 | -81.89 | -123.01 | -168.34 | -201.07 | -168.91 | -106.51 | -1316.86 | -2561.79 | -3806.99 | -3824.81 | -2555.87 | -1286.92 | -17.98 | - | - | - |
ROCE % |
200.10 | -208.25 | -450.58 | -483.68 | -701.14 | -343.41 | -173.81 | -255.86 | -304.82 | -257.34 | -155.59 | -165.90 | -94.17 | -63.03 | -34.05 | -90.18 | -89.07 | -89.38 | -83.41 | -40.01 | -46.38 | -51.95 | -62.10 | -50.93 | -46.54 | -36.80 | -25.15 | -28.76 | -21.20 | -19.06 | -18.35 | -19.09 | -22.09 | -21.15 | -18.91 | -18.06 | -18.28 | -16.89 | -16.92 | 38.34 | 103.88 | 152.32 | 214.24 | 224.42 | 198.65 | 179.75 | 130.82 | 318.70 | 534.01 | 645.87 | 491.75 | 491.75 | 243.50 | 104.42 | - | - | - | - |
Current Ratio |
1.1 | 1.1 | 1.1 | 0.9 | 1.0 | 1.1 | 1.3 | 1.5 | 1.2 | 1.3 | 1.1 | 1.2 | - | 1.3 | 1.6 | 1.7 | 1.8 | 1.9 | 1.5 | 1.5 | 1.5 | 1.5 | 1.6 | 1.6 | 1.6 | 1.6 | 1.8 | 1.8 | 1.8 | 1.8 | 2.3 | 2.3 | 2.3 | 2.3 | 2.4 | 2.4 | 2.4 | 2.4 | 2.4 | 2.4 | 2.4 | 2.4 | 0.8 | 0.8 | 0.8 | 0.8 | 0.5 | 0.5 | 0.5 | 0.5 | 0.4 | - | - | 0.4 | - | - | - | - |
DSO |
29.1 | 34.3 | - | 36.0 | 39.8 | 48.4 | - | 43.0 | 59.4 | 56.4 | - | 20.6 | 12.4 | 28.8 | - | 16.9 | 20.8 | 27.9 | 28.5 | 28.4 | 30.0 | 32.5 | 35.3 | 37.1 | 36.8 | 35.4 | 26.4 | 28.4 | 27.9 | 31.5 | 30.0 | 31.4 | 32.6 | 43.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
2270.3 | 778.7 | - | 2409.2 | 1888.0 | 2524.2 | - | 1399.5 | 800.5 | 123.7 | - | 298.9 | 145.1 | 295.2 | - | 401.9 | 403.2 | 410.2 | - | 583.9 | 464.7 | 455.9 | - | 366.8 | 566.9 | 524.9 | - | 452.6 | 435.3 | 310.3 | - | 527.9 | - | - | - | - | - | - | - | - | - | - | - | - | 19.0 | 17.5 | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
1035.1 | 379.4 | - | 1376.0 | 942.3 | 1771.6 | - | 1580.5 | 1151.4 | 374.4 | - | 573.8 | 410.1 | 716.6 | - | 406.2 | 645.3 | 752.8 | - | 931.1 | 741.1 | 1290.4 | - | 1605.1 | 2480.6 | 1505.9 | - | 560.1 | 538.7 | 732.4 | - | 1868.2 | - | - | - | - | - | - | - | - | - | - | - | - | 168.9 | 233.8 | - | - | 905.3 | 224.5 | - | - | - | - | - | - | - | - |
Operating Cycle |
2299.4 | 813.1 | - | 2445.2 | 1927.8 | 2572.7 | - | 1442.5 | 860.0 | 180.1 | - | 319.4 | 157.4 | 324.0 | - | 418.8 | 424.1 | 438.1 | 28.5 | 612.3 | 494.7 | 488.4 | 35.3 | 403.9 | 603.7 | 560.3 | 26.4 | 480.9 | 463.2 | 341.8 | 30.0 | 559.2 | 32.6 | 43.9 | - | - | - | - | - | - | - | - | - | - | 19.0 | 17.5 | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
1264.3 | 433.7 | - | 1069.2 | 985.5 | 801.0 | - | -138.0 | -291.4 | -194.4 | - | -254.3 | -252.7 | -392.6 | - | 12.6 | -221.2 | -314.6 | 28.5 | -318.9 | -246.4 | -802.0 | 35.3 | -1201.2 | -1876.9 | -945.6 | 26.4 | -79.1 | -75.5 | -390.6 | 30.0 | -1309.0 | 32.6 | 43.9 | - | - | - | - | - | - | - | - | - | - | -150.0 | -216.3 | - | - | -905.3 | -224.5 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Travere Therapeutics, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.